Zymeworks Inc. Cash Flow Statement
ZYME / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Zymeworks Inc. used $33M in operating cash flow and negative free cash flow of $35M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$81.1M | -$122.7M | -$118.7M | -$180.6M | -$211.8M | -$180.6M |
| Depreciation & Amortization | - | - | - | $3.4M | $3.7M | $3.4M |
| Operating Cash Flow | -$33.0M | -$110.1M | -$118.3M | -$151.4M | -$192.5M | -$151.4M |
| Capital Expenditures | $1.5M | $2.0M | $2.5M | $4.3M | $12.4M | $4.3M |
| Free Cash Flow | -$34.5M | -$112.0M | -$120.8M | -$155.7M | -$204.9M | -$155.7M |
| Share Buybacks | $41.7M | $30.1M | $0 | - | - | - |
| FCF Margin | -32.6% | -146.8% | -158.9% | -399.8% | - | - |